Drug Topics
SEPTEMBER 9, 2024
LEO Pharma presented data from 2 of the largest multinational real-world studies on the prevalence, severity and treatment of chronic hand eczema at the European Society of Contact Dermatitis congress.
Pharmacy Times
SEPTEMBER 9, 2024
Presenter Krish Patel, MD, discusses the use of epcoritamab (Epkinly; AbbVie) and glofitamab (Columvi; Genentech) in aggressive B-cell lymphomas as monotherapies and in combination regimens.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
SEPTEMBER 9, 2024
Whereby gastroparesis can hinder the absorption of oral medications in the stomach, Tonix Pharmaceuticals is promoting alternative migraine treatments that bypass the digestive system.
STAT
SEPTEMBER 9, 2024
Going to the doctor is already tricky enough for people with chronic symptoms of Lyme disease. Their concerns often dismissed by mainstream medicine, those patients now face an additional hurdle: ruling out long Covid. The two illnesses — one seeping in over the course of decades and another suddenly springing to life on a massive scale — share many qualities, including being widely misunderstood.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
SEPTEMBER 9, 2024
Drug Topics discussed independent pharmacy advocacy and PBM reform on the federal level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.
STAT
SEPTEMBER 9, 2024
The Biden administration on Monday announced it would finalize a highly anticipated proposal meant to force health insurers to cover mental health care on the same basis as physical health conditions. It is the latest salvo in a long-running federal government effort to crack down on insurance plans skimping on treatment for conditions including anxiety, depression, and addiction.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
SEPTEMBER 9, 2024
On Sunday, a small biotech company called Summit Therapeutics won a remarkable victory, saying its experimental drug outperformed Merck’s Keytruda , the world’s best-selling drug, in non-small cell lung cancer, the disease that represents Keytruda’s biggest market. By itself, Summit’s victory would be a dramatic story, although not an unheard of one in the unpredictable world of biotechnology.
Fierce Healthcare
SEPTEMBER 9, 2024
The Biden administration is strengthening private health coverage for individuals seeking mental health and substance use disorder (SUD) care in a final rule unveiled Monday. | The feds are attempting to better regulate mental health coverage by bolstering protections around prior authorization, step therapy and provider networks.
STAT
SEPTEMBER 9, 2024
One of the biopharma industry’s marvels of the 2020s has been the enormous medical and financial success of the GLP-1 class of drugs. But the path to commercialization of these therapies was far more complex than most understand, and some of the earliest history has never been presented. Beginning in 1988, I was part of what I believe was the earliest commercial effort to develop GLP-1 as a metabolic therapy.
Fierce Healthcare
SEPTEMBER 9, 2024
Pittsburgh-based Highmark has signed on as AppliedVR's first commercial payer partner, making its flagship VR device for chronic lower back pain a covered treatment for more than 4 million plan mem | Pittsburgh-based Highmark has signed on as AppliedVR's first commercial payer partner, making its flagship VR device for chronic lower back pain a covered treatment for more than 4 million plan members.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
SEPTEMBER 9, 2024
WASHINGTON — The House Monday passed a bill by 306 to 81 votes to make drug companies stop doing business with some Chinese biotechs within eight years if they want to remain in good standing with the federal government. The BIOSECURE Act would prohibit the U.S. government from contracting with, or providing grants to, companies that do business with a “biotechnology company of concern.
Fierce Healthcare
SEPTEMBER 9, 2024
The four largest pharmacy benefit managers in the U.S. | The four largest pharmacy benefit managers in the United States control 70% of the national market, according to new data from the American Medical Association.
STAT
SEPTEMBER 9, 2024
Elite athletes train and compete under a watchful eye. Fans and coaches track and measure every step, roll, or throw. But for athletes with a spinal cord injury, a key facet of their experience is unknown: neuropathic pain. Unlike musculoskeletal pain — say, from breaking your leg — neuropathic pain resides in the nervous system. And treating it is tricky: you can’t just pop an Advil or Tylenol and wait for the pain to subside.
Fierce Healthcare
SEPTEMBER 9, 2024
Retail pharmacy chain Rite Aid has emerged out of bankruptcy after slashing about $2 billion from its debt, the company announced last week. | Retail pharmacy chain Rite Aid has emerged out of bankruptcy after slashing about $2 billion from its debt, the company announced last week.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
SEPTEMBER 9, 2024
The study authors suggest that annual screening for women aged 40 and older may be beneficial, but warn of the increased risk of false positive results.
Fierce Healthcare
SEPTEMBER 9, 2024
The state of Texas is suing the Department of Health and Human Services in a Texas federal district court for a rule it finalized in April that gives healthcare organizations more discret | The state of Texas filed a lawsuit last week that argues a rule finalized by HHS' Office for Civil Rights is illegal. The Texas attorney general says HHS does not have statutory authority to keep information from law enforcement.
STAT
SEPTEMBER 9, 2024
NEW YORK — One Brooklyn Health, a safety net hospital system that serves some of this city’s poorest and sickest patients, would seem to be exactly the place to benefit most from the effort to remove race from calculations that assess kidney disease. The patients — mostly Black and insured by Medicaid or Medicare — are a case study in the disparities that run through American kidney care: A large number have advanced disease and require dialysis, but just a handful ge
Pharmaceutical Commerce
SEPTEMBER 9, 2024
In the second part of her interview with Pharma Commerce Editor Nicholas Saraceno, Meghan Mullooly, Archbow Consulting’s Vice President, offers advice to pharma manufacturers for successfully applying digital solutions to their patient support programs.
STAT
SEPTEMBER 9, 2024
CUPERTINO, Calif. — Apple on Monday announced a new Apple Watch feature that will warn users they may have sleep apnea. It’s the latest advance in the company’s decade-long effort to sell its wearable as a tool that can help people live healthier lives. Additionally, the company announced more hearing health features for its wireless earbuds.
pharmaphorum
SEPTEMBER 9, 2024
Discover how Chiesi is leading the way in pharmaceutical sustainability by partnering with EcoVadis and implementing innovative practices. Learn how they are making a positive impact on the environment and society.
STAT
SEPTEMBER 9, 2024
Duchenne muscular dystrophy has seen more progress in the past 15 months (give or take) than in the last couple of decades combined. In that time, the Food and Drug Administration has approved three new therapies: Elevidys (delandistrogene moxeparvovec-rokl), the first micro-dystrophin gene therapy; Duvyzat (givinostat), a non-steroidal HDAC inhibitor; and Agamree (vamorolone), a new corticosteroid.
European Pharmaceutical Review
SEPTEMBER 9, 2024
A report from Frontier Economics has highlighted the major benefit industry clinical trials have had on UK’s economy. For instance, it has supported its growth and the job market, the research showed. Of the 65,000 jobs generated, 21,000 individuals were employed directly by the pharmaceutical industry to deliver trials, according to the data. While industry clinical trials in the UK have reduced , the Association of the British Pharmaceutical Industry (ABPI) stated that if the activity assumes
The Checkup by Singlecare
SEPTEMBER 9, 2024
When you’re dealing with a nasty virus, one of the most popular over-the-counter medication options is Vicks NyQuil. NyQuil can treat a variety of cold symptoms, such as sore throat, runny nose, coughing, sneezing, and flu symptoms like body aches or fever. Another bonus is that NyQuil can cause drowsiness, which can help you more easily sleep throughout the night rather than tossing and turning until the wee hours.
STAT
SEPTEMBER 9, 2024
With strong data released over the weekend, an experimental Chinese drug showed it could one day become an important therapy for lung cancer patients. But that doesn’t necessarily threaten the market dominance of Keytruda, a top Merck executive said — and some analysts agree. “I see these results as important, but preliminary,” Merck Chief Medical Officer Eliav Barr told STAT, reacting to the presentation Sunday of a Phase 3 clinical trial involving ivonescimab, a dru
Fierce Healthcare
SEPTEMBER 9, 2024
Labor costs and availability were major pain points for hospital and health system operations during the pandemic but finally look to be leveling out even as demand for care services remains high, | Though post-pandemic demand and an aging population are still at play, hospitals and health systems have made gains on rampant wage inflation and job openings during the past year, Fitch Ratings wrote in a new report.
Pharmacy Times
SEPTEMBER 9, 2024
Datopotamab deruxtecan was effective in patients with TROP2-QCS biomarker-positive tumors for non–small cell lung cancer
Fierce Healthcare
SEPTEMBER 9, 2024
Health system executives in charge of their organization’s revenue cycle are fretting about their dealings with payers, with many noting elevated denial rates across the board and within Medicare A | Forty-one percent of surveyed revenue cycle leaders report denial rates higher than 3.1%, and nearly all describe payer challenges as a top concern.
pharmaphorum
SEPTEMBER 9, 2024
Summit Therapeutics and Akeso's ivonescimab tops Merck's Keytruda in head-to-head phase 3 trial in first-line NSCLC, reported at WCLC.
STAT
SEPTEMBER 9, 2024
Triumphant music plays as cancer patients go camping, do some gardening, and watch fireworks in ads for Opdivo+Yervoy , a combination of immunotherapies to treat metastatic melanoma and lung cancer. Ads for Skyrizi , a medicine to treat plaque psoriasis and other illnesses, show patients snorkeling and riding bikes — flashing their rash-free elbows.
Pharmacy Times
SEPTEMBER 9, 2024
Pharmacists are encouraged to leverage their trusted community role to help manage the anticipated health care burden from respiratory infections this season.
STAT
SEPTEMBER 9, 2024
After leading his previous company through a back-to-back IPO and M&A deal, the former chief executive of RayzeBio has raised $370 million to develop autoimmune therapies he believes could be “mega-blockbusters.” Those drugs are being developed by San Diego startup Candid Therapeutics, which launched Monday with financing from more than 20 investors.
Fierce Healthcare
SEPTEMBER 9, 2024
I’m honored to introduce the second edition of the Fierce 50, where we once again spotli | In this year's Fierce 50 special report, we are highlighting the innovators and leaders who are shaping the future of healthcare, pharma and biotechnology. This year's honorees demonstrate unwavering dedication and creativity, propelling these industries forward.
STAT
SEPTEMBER 9, 2024
Relay Therapeutics disclosed encouraging results for its key breast cancer drug and plans to advance the experimental treatment, called RLY-2608, to a late-stage clinical trial, the biotech firm said on Monday. The new data come from an open label phase 1/2 trial on RLY-2608 combined with fulvestrant, an endocrine therapy for breast cancer, showing a third of patients with measurable disease responded to the treatment.
pharmaphorum
SEPTEMBER 9, 2024
AI biomarker could help identify lung cancer patients most likely to benefit from AstraZeneca and Daiichi Sankyo's TROP2 drug Dato-DXd.
Expert insights. Personalized for you.
234 
Let's personalize your content